COST-EFFECTIVENESS ANALYSIS OF ANEMIA TREATMENT AMONG\CHRONIC KIDNEY DISEASE PATIENTS AT KIEN GIANG GENERAL HOSPITAL
 
More details
Hide details
1
University of Medicine Pham Ngoc Thach
2
University of Medicine and Pharmacy at Ho Chi Minh City
3
KienGiang General Hospital
4
Buon Ma Thuot University
5
University of Medicine and Pharmacy at Ho Chi Minh City 70000
Online publication date: 2018-05-16
Publication date: 2018-05-16
 
Eurasian J Anal Chem 2018;13(3):emEJAC04004
 
KEYWORDS
ABSTRACT
Background: Anemia due to chronic kidney disease (CKD) is a dangerous complication that causes a burden on the patients and society. However, it can be treated with erythropoietin (EPO). There is a lack of studies evaluating the cost-effectivenessof EPO in Vietnam in treating anemic complications, leading to difficulties in decision-making in terms of prescriptions. Objectives:This studied was undertaken to explore the incremental cost-effectiveness ratio (ICER) of EPO in maintaining different Hb levels when treating anemia in hemodialysis patients due to end-stage CKD at KienGiang General Hospital, Vietnam, in 2017. Methods: Cost-effectiveness analysis (CEA) was performed based on the decision tree and Markov models. The cost and quality-of-life data was collected via face-to-face interviews using the KDQOL-SF questionnaire.The probability coefficients of the model were sought systemically from the randomised clinical trials. Results: The ICERs indicated that there were no interventions that were cost-effective in relation to gross domestic product (GDP) of Vietnam. However, patients with the target Hb level of>10-11 g/dLwere inferred to receive the most benefitfrom the treatment, as indicated by the corresponding lowest ICER. Conclusion: The findings of this study should be proposed to policy decision makers to set up guidelines for appropriate and cost-effective use of EPO in hospitals in Vietnam.
eISSN:1306-3057